| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -2.9 | -1.2 |
| Net income | -2.9 | -1.2 |
| EPS (diluted, $ a share) | $-1.89 | $-3.77 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: ERNA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Ernexa Therapeutics Inc.: key numbers
- Share price
- $1.63Close, Nov 17
- Market cap
- $2.76M
- Shares outstanding
- 1.69MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Ernexa Therapeutics Inc.
All →Ernexa Therapeutics Investor Presentation
Ernexa Therapeutics Inc. has made available a formal investor presentation for October 2026. The presentation is intended to provide strategic updates and company information to investors and is accessible via the company's investor relations website.
Ernexa Therapeutics Investor Presentation
Ernexa Therapeutics Inc. has made available a new corporate fact sheet and a formal investor presentation for September 2026. The materials, filed under Item 7.01, provide updated corporate information and strategic highlights for investors and are accessible via the company's investor relations website.
Ernexa Therapeutics Leadership Change
Ernexa Therapeutics Inc. appointed Robert J. Spiegel, M.D. to its Board of Directors, effective September 14, 2026. Dr. Spiegel will be compensated according to the company's existing Board of Directors Compensation Plan and will serve until his successor is elected.
- Counterparty
- Robert J. Spiegel, M.D.